March Bio Starts Phase 2 Trial for Rare Blood Cancer
By Karen Roman March Biosciences said it started Phase 2 trial for MB-105, its CAR-T therapy for patients with relapsed or refractory CD5+ T-cell lymphoma. The test will take place at leading cancer centers across the country, with the first...